Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas

[1]  Zhi Rong Qian,et al.  MicroRNAs in Human Pituitary Adenomas , 2014, International journal of endocrinology.

[2]  E. Holmberg,et al.  The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. , 2014, European journal of endocrinology.

[3]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[4]  C. Croce,et al.  Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. , 2012, The Journal of clinical endocrinology and metabolism.

[5]  Š. Pospíšilová,et al.  MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. , 2012, Blood.

[6]  M. Geraci,et al.  Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors. , 2011, Endocrinology.

[7]  B. Scheithauer,et al.  MicroRNAs in the Human Pituitary , 2011, Endocrine pathology.

[8]  P. Igaz,et al.  MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas , 2011, Pituitary.

[9]  G. Salles,et al.  Cyclin-dependent kinase 1 expression is inhibited by p16INK4a at the post-transcriptional level through the microRNA pathway , 2011, Oncogene.

[10]  R. Wallace,et al.  Demographic differences in incidence for pituitary adenoma , 2011, Pituitary.

[11]  P. Igaz,et al.  Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. , 2010, The Journal of clinical endocrinology and metabolism.

[12]  M. Korbonits,et al.  Cyclins and their related proteins in pituitary tumourigenesis , 2010, Molecular and Cellular Endocrinology.

[13]  Anindya Dutta,et al.  MiR-322/424 and -503 Are Induced during Muscle Differentiation and Promote Cell Cycle Quiescence and Differentiation by Down-Regulation of Cdc25A , 2010, Molecular biology of the cell.

[14]  D. Desiderio,et al.  Signaling pathway networks mined from human pituitary adenoma proteomics data , 2010, BMC Medical Genomics.

[15]  J. Lachuer,et al.  Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. , 2010, The Journal of clinical endocrinology and metabolism.

[16]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[17]  A. Beckers.  Higher prevalence of clinically relevant pituitary adenomas confirmed , 2010, Clinical endocrinology.

[18]  Lei Shi,et al.  MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation , 2010, Brain Research.

[19]  Qiang Yu,et al.  miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. , 2009, Genes & development.

[20]  Lin Zhang,et al.  Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21 , 2009, Cell cycle.

[21]  K. Helin,et al.  NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint , 2009, Nature Cell Biology.

[22]  A. Beckers,et al.  The epidemiology and genetics of pituitary adenomas. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[23]  S. Manenti,et al.  CDC25A: a rebel within the CDC25 phosphatases family? , 2008, Anti-cancer agents in medicinal chemistry.

[24]  N. LaRusso,et al.  MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. , 2008, The Journal of clinical investigation.

[25]  C. Stratakis,et al.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[26]  Qing-Yuan Sun,et al.  Cdc25A promotes G2/M transition in oocytes , 2008, Cell Cycle.

[27]  A. Gill,et al.  Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. , 2008, Endocrinology.

[28]  B. Frey,et al.  Using expression profiling data to identify human microRNA targets , 2007, Nature Methods.

[29]  J. Lachuer,et al.  A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. , 2007, Endocrine-related cancer.

[30]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[31]  George A Calin,et al.  Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas , 2007, Journal of cellular physiology.

[32]  Y. Katayama,et al.  Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas , 2007, Journal of Neuro-Oncology.

[33]  A. Heaney.  Pituitary tumour pathogenesis. , 2006, British medical bulletin.

[34]  T. Hsia,et al.  INHIBITION OF LUNG CANCER CELL GROWTH BY QUERCETIN GLUCURONIDES VIA G2/M ARREST AND INDUCTION OF APOPTOSIS , 2006, Drug Metabolism and Disposition.

[35]  Xianquan Zhan,et al.  Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. , 2005, Cancer research.

[36]  S. Czirják,et al.  Differential gene expression in pituitary adenomas by oligonucleotide array analysis. , 2005, European journal of endocrinology.

[37]  Y. Katayama,et al.  The p15INK4b/p16INK4a/RB1 Pathway Is Frequently Deregulated in Human Pituitary Adenomas , 2005 .

[38]  Jing Zhao,et al.  Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[39]  J. Rudolph,et al.  Cdc25 phosphatases and cancer. , 2004, Chemistry & biology.

[40]  H. Kuwano,et al.  The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Jiri Bartek,et al.  Regulation of G2/M events by Cdc25A through phosphorylation‐dependent modulation of its stability , 2002, The EMBO journal.

[42]  S. Melmed,et al.  Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells. , 2002, The Journal of endocrinology.

[43]  W. Farrell,et al.  Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. , 2001, Carcinogenesis.

[44]  D. Brat,et al.  Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. , 2001, The Journal of clinical endocrinology and metabolism.

[45]  A. Jauch,et al.  Chromosomal aberrations in sporadic pituitary tumors , 2001, International journal of cancer.

[46]  Nagy,et al.  Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland , 2000, Clinical endocrinology.

[47]  M. Korbonits,et al.  Cyclin D and cyclin E expression in normal and adenomatous pituitary. , 2000, European journal of endocrinology.

[48]  U. Mansmann,et al.  Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array , 1999, International journal of cancer.

[49]  T. Okamura,et al.  Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization. , 1999, Cancer genetics and cytogenetics.

[50]  F. Waldman,et al.  Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization. , 1999, Journal of neurosurgery.

[51]  R. Fahlbusch,et al.  Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[52]  S. Asa,et al.  The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. , 1996, The Journal of clinical endocrinology and metabolism.

[53]  D. Beach,et al.  Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins , 1991, Cell.

[54]  K. Sadhu,et al.  Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Dashi Zhi,et al.  The experimental study of miRNA in pituitary adenomas. , 2013, Turkish neurosurgery.

[56]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[57]  Yusuke Yamamoto,et al.  Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Y. Katayama,et al.  The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. , 2005, Journal of neuropathology and experimental neurology.

[59]  S. Asa,et al.  The 2004 World Health Organization classification of pituitary tumors: What is new? , 2005, Acta Neuropathologica.

[60]  吉田 武史.  The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer , 2005 .

[61]  K. Schluens,et al.  Genomic Instability in Pituitary Adenomas , 2004, Pituitary.

[62]  T. Kameya,et al.  Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: Difference among functioning, silent, and other nonfunctioning adenomas , 2002, Endocrine pathology.